- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- hetero-6-6-6-6-mer
- Ligands
- 6 x ILE- SER- GLU- VAL: POLIOVIRUS TYPE 3(Non-covalent)
- 6 x J80: (METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE(Non-covalent)
J80.2: 18 residues within 4Å:- Chain A: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain C: A.24, I.25
16 PLIP interactions:15 interactions with chain A, 1 interactions with chain C- Hydrophobic interactions: A:I.108, A:I.108, A:Y.110, A:Y.110, A:F.132, A:Y.157, A:Y.157, A:Y.157, A:P.179, A:I.181, A:V.197, A:F.236, A:F.236, A:F.236, C:A.24
- pi-Stacking: A:Y.203
J80.5: 18 residues within 4Å:- Chain E: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain G: A.24, I.25
16 PLIP interactions:15 interactions with chain E, 1 interactions with chain G- Hydrophobic interactions: E:I.108, E:I.108, E:Y.110, E:Y.110, E:F.132, E:Y.157, E:Y.157, E:Y.157, E:P.179, E:I.181, E:V.197, E:F.236, E:F.236, E:F.236, G:A.24
- pi-Stacking: E:Y.203
J80.8: 18 residues within 4Å:- Chain I: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain K: A.24, I.25
16 PLIP interactions:15 interactions with chain I, 1 interactions with chain K- Hydrophobic interactions: I:I.108, I:I.108, I:Y.110, I:Y.110, I:F.132, I:Y.157, I:Y.157, I:Y.157, I:P.179, I:I.181, I:V.197, I:F.236, I:F.236, I:F.236, K:A.24
- pi-Stacking: I:Y.203
J80.11: 18 residues within 4Å:- Chain M: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain O: A.24, I.25
16 PLIP interactions:15 interactions with chain M, 1 interactions with chain O- Hydrophobic interactions: M:I.108, M:I.108, M:Y.110, M:Y.110, M:F.132, M:Y.157, M:Y.157, M:Y.157, M:P.179, M:I.181, M:V.197, M:F.236, M:F.236, M:F.236, O:A.24
- pi-Stacking: M:Y.203
J80.14: 18 residues within 4Å:- Chain Q: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain S: A.24, I.25
16 PLIP interactions:15 interactions with chain Q, 1 interactions with chain S- Hydrophobic interactions: Q:I.108, Q:I.108, Q:Y.110, Q:Y.110, Q:F.132, Q:Y.157, Q:Y.157, Q:Y.157, Q:P.179, Q:I.181, Q:V.197, Q:F.236, Q:F.236, Q:F.236, S:A.24
- pi-Stacking: Q:Y.203
J80.17: 18 residues within 4Å:- Chain U: I.108, T.109, Y.110, F.132, I.155, Y.157, P.179, S.180, I.181, I.192, V.194, V.197, Y.203, D.235, F.236, L.239
- Chain W: A.24, I.25
16 PLIP interactions:1 interactions with chain W, 15 interactions with chain U- Hydrophobic interactions: W:A.24, U:I.108, U:I.108, U:Y.110, U:Y.110, U:F.132, U:Y.157, U:Y.157, U:Y.157, U:P.179, U:I.181, U:V.197, U:F.236, U:F.236, U:F.236
- pi-Stacking: U:Y.203
- 6 x MYR: MYRISTIC ACID(Covalent)
MYR.3: 8 residues within 4Å:- Chain D: G.1, A.2, Y.31
- Chain H: V.4, T.27, I.29, Y.31
- Ligands: MYR.6
3 PLIP interactions:2 interactions with chain H, 1 interactions with chain D- Hydrophobic interactions: H:I.29
- Hydrogen bonds: H:T.27, D:A.2
MYR.6: 4 residues within 4Å:- Chain H: G.1, A.2, Y.31
- Ligands: MYR.3
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:A.2
MYR.9: 4 residues within 4Å:- Chain L: G.1, A.2, Y.31
- Ligands: MYR.12
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:A.2
MYR.12: 8 residues within 4Å:- Chain L: V.4, T.27, I.29, Y.31
- Chain P: G.1, A.2, Y.31
- Ligands: MYR.9
3 PLIP interactions:2 interactions with chain L, 1 interactions with chain P- Hydrophobic interactions: L:I.29
- Hydrogen bonds: L:T.27, P:A.2
MYR.15: 8 residues within 4Å:- Chain T: G.1, A.2, Y.31
- Chain X: V.4, T.27, I.29, Y.31
- Ligands: MYR.18
3 PLIP interactions:1 interactions with chain T, 2 interactions with chain X- Hydrogen bonds: T:A.2, X:T.27
- Hydrophobic interactions: X:I.29
MYR.18: 4 residues within 4Å:- Chain X: G.1, A.2, Y.31
- Ligands: MYR.15
1 PLIP interactions:1 interactions with chain X- Hydrogen bonds: X:A.2
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Grant, R.A. et al., Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr.Biol. (1994)
- Release Date
- 1996-07-11
- Peptides
- POLIOVIRUS TYPE 3: AEIMQU
POLIOVIRUS TYPE 3: BFJNRV
POLIOVIRUS TYPE 3: CGKOSW
POLIOVIRUS TYPE 3: DHLPTX - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1E
1I
1M
1Q
1U
1B
2F
2J
2N
2R
2V
2C
3G
3K
3O
3S
3W
3D
4H
4L
4P
4T
4X
4
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.80 Å
- Oligo State
- hetero-6-6-6-6-mer
- Ligands
- 6 x ILE- SER- GLU- VAL: POLIOVIRUS TYPE 3(Non-covalent)
- 6 x J80: (METHYLPYRIDAZINE PIPERIDINE BUTYLOXYPHENYL)ETHYLACETATE(Non-covalent)
- 6 x MYR: MYRISTIC ACID(Covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Grant, R.A. et al., Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr.Biol. (1994)
- Release Date
- 1996-07-11
- Peptides
- POLIOVIRUS TYPE 3: AEIMQU
POLIOVIRUS TYPE 3: BFJNRV
POLIOVIRUS TYPE 3: CGKOSW
POLIOVIRUS TYPE 3: DHLPTX - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1E
1I
1M
1Q
1U
1B
2F
2J
2N
2R
2V
2C
3G
3K
3O
3S
3W
3D
4H
4L
4P
4T
4X
4